The Added Value of Contrast-Enhanced 68 Ga-FAPI-04 PET/MRI Over 18 F-FDG PET/CT in Hepatocellular Carcinoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38914096.
- Also identified by DOI 10.1097/RLU.0000000000005342.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 43-year-old man with chronic hepatitis B and elevated alpha-fetoprotein levels showed no malignant evidence on 18 F-FDG PET/CT. However, subsequent assessment using 68 Ga-FAPI-04 PET/MR identified a lesion with increased FAPI uptake in the liver, coupled with detailed enhancement patterns on MRI, leading to a diagnosis of hepatocellular carcinoma, later confirmed by pathology. This case highlights the pivotal role of integrated 68 Ga-FAPI-04 PET and enhanced MRI in refining hepatocellular carcinoma diagnostics, advancing a more nuanced imaging approach over conventional modalities for comprehensive evaluation of hepatic lesions.
Medical subject headings
- Liver Neoplasms
- Carcinoma, Hepatocellular
- Fluorodeoxyglucose F18
- Magnetic Resonance Imaging
- Positron Emission Tomography Computed Tomography
- Contrast Media